A Phase I, Randomised, 2 Period Cross Over Study to Determine the Comparative Bioavailability of Two Different Oral Formulations of AZD2281 in Cancer Patients With Advanced Solid Tumours
Latest Information Update: 11 Dec 2024
At a glance
- Drugs Olaparib (Primary)
- Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 08 May 2024 Planned End Date changed from 31 Dec 2024 to 31 Mar 2025.
- 25 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 19 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.